Salubris(SZ:002294) Guolian Minsheng Securities·2026-03-15 10:32Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical sector, particularly highlighting the potential of the drug JK07 from the company Sinopharm [6]. Core Insights - The pharmaceutical sector is believed to have entered a bottoming phase, with several innovative drug companies showing signs of valuation recovery due to high expectations for overseas sales and recent breakthroughs [3][4]. - The report emphasizes the importance of innovation and international expansion as the underlying logic for the current pharmaceutical industry cycle, with a focus on innovative drugs and supply chain improvements [4]. Summary by Sections Section 1: JK07's Potential - JK07 is positioned to potentially become a blockbuster drug comparable to Novartis' Entresto, with significant clinical data expected in 2026 [5][52]. - The drug targets heart failure, a condition with substantial unmet clinical needs, and is designed to activate the ErbB4 pathway while blocking ErbB3 signaling, which may enhance its therapeutic efficacy [35][40]. Section 2: Pharmaceutical Market Review - The pharmaceutical index experienced a slight decline of 0.22% during the week of March 9-13, underperforming compared to the ChiNext and CSI 300 indices [53][54]. - The total trading volume for pharmaceuticals was 409.68 billion yuan, accounting for 3.30% of the total market, which is below the historical average of 7.07% since 2013 [70]. Section 3: Market Trends and Valuation - The report notes a decrease in the valuation of the pharmaceutical sector, with a current PE ratio of 30.34, which is below the historical average [67]. - The industry is currently experiencing a valuation premium that is significantly lower than historical averages, indicating potential investment opportunities as valuations normalize [67]. Section 4: Stock Performance - The report highlights the top-performing stocks in the pharmaceutical sector, including Yingke Medical and Chitianhua, which saw significant gains during the week [74]. - Conversely, stocks like Yueshen Health and Yifang Bio-U faced notable declines, indicating a mixed performance across the sector [74].